biostudies-literatureYan HShanghai Academic/Technology Research LeaderShanghai Hengrui Pharmaceuticals Co., Ltde087617https://www.ebi.ac.uk/biostudies/studies/S-EPMC11404262biostudies-literatureUnknown14(8)<h4>Introduction</h4>Heart failure with preserved ejection fraction (HFpEF) is a prevalent comorbidity among patients with end-stage kidney disease. Although sodium-glucose cotransporter 2 inhibitors are validated in treating heart failure and ameliorating left ventricular hypertrophy among non-dialysis patients, the effects on dialysis patients are unknown. We previously investigated the pharmacokinetics of henagliflozin in patients undergoing haemodialysis (HD) or peritoneal dialysis (PD) and clarified its safety.<h4>Methods and analysis</h4>This multicentre, randomised, double-blind, placebo-controlled trial is being conducted at three hospitals in Shanghai, China. A target of 108 HD or PD patients with HFpEF are randomly allocated to treatment group (henagliflozin 5 mg/day in addition BMJ openEffect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial.PMC1140426222XD1431400Pu JLiu SZhou YJiang MWang JZhang WFang YLi YLi ZFang WQi YGu LWang WPang HYan HLu RfalseEffect of henagliflozin on left ventricular mass index in dialysis patients with HFpEF (HELD-HF): protocol for a multicentre, randomised, double-blind, placebo-controlled trial.<h4>Introduction</h4>Heart failure with preserved ejection fraction (HFpEF) is a prevalent comorbidity among patients with end-stage kidney disease. Although sodium-glucose cotransporter 2 inhibitors are validated in treating heart failure and ameliorating left ventricular hypertrophy among non-dialysis patients, the effects on dialysis patients are unknown. We previously investigated the pharmacokinetics of henagliflozin in patients undergoing haemodialysis (HD) or peritoneal dialysis (PD) and clarified its safety.<h4>Methods and analysis</h4>This multicentre, randomised, double-blind, placebo-controlled trial is being conducted at three hospitals in Shanghai, China. A target of 108 HD or PD patients with HFpEF are randomly allocated to treatment group (henagliflozin 5 mg/day in addition 2024-01-01T00:00:00Z2024 Aug2026-06-07T07:42:41.905Z2026-06-07T03:12:12.451ZS-EPMC114042623919146410.1136/bmjopen-2024-087617